Cystic Fibrosis

Cystic fibrosis is a life threatening, inherited disease of the exocrine glands. The condition primarily affects the digestive and respiratory systems which become clogged with a thick, sticky mucus. Cystic fibrosis is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in an excess of salt and water passing into cells, causing a thick, sticky mucus to build up in bodily passageways.

Cystic Fibrosis (CF)

Cystic fibrosis is a genetic condition that affects the production and flow of mucus within the lungs and digestive system, parts of the body that then become clogged with a thick, sticky mucus.

Cystic Fibrosis Epidemiology

Gene Therapy as a Potential Cure for Cystic Fibrosis

Cystic Fibrosis Evolution

Could CRISPR Repair CFTR in Cystic Fibrosis Patients?

Cystic Fibrosis Treatment

Cystic Fibrosis Diagnosis

Cystic Fibrosis Prognosis

Cystic Fibrosis Questions

Cystic Fibrosis and Infertility

Cystic Fibrosis Research

Cystic Fibrosis History

See more featured articles »

Cystic Fibrosis Screening

Lung Transplantation for Cystic Fibrosis

Cystic Fibrosis Causes

Cystic Fibrosis Facts

Sweat Test for Cystic Fibrosis

Cystic Fibrosis Symptoms

Genetics of Cystic Fibrosis

Coping With Cystic Fibrosis

Cystic Fibrosis and Salty Skin

Tests for Cystic Fibrosis During Pregnancy

Latest Cystic Fibrosis News and Research

Deep-learning tissue clocks reveal how organs age and leave disease-linked signals in blood

Deep learning applied to more than 25,000 histopathology slides revealed tissue-specific structural signatures of biological aging that tracked telomere attrition, pathology, comorbidity, and molecular changes more closely than chronological age alone.

18 Aug 2026

AI-based "tissue clocks" measure the biological age of human organs

AI-based "tissue clocks" can estimate the biological age of human organs from histological images, researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Ludwig Boltzmann Institute for Network Medicine (LBI-NetMed) at the University of Vienna showed.

14 Aug 2026

Study sheds new light on the physiological roles of protein quality control at the ribosome

Scientists at the Center for Molecular Medicine Cologne (CMMC) and the CECAD Cluster of Excellence on Aging Research have demonstrated in a biomedical study that ribosomes, the protein factories of our cells, face an unusually tough challenge when building large, membrane‑embedded proteins.

12 Aug 2026

Advances in DNA technology are reshaping preventive healthcare

A new review highlights how advances in DNA technology are reshaping the future of healthcare by shifting the focus from treatment to prevention.

6 Aug 2026

Using DNA sequencing for accurate identification of microbial infections in cystic fibrosis patients

Lung infections are a constant risk for people living with cystic fibrosis (CF), a life-threatening genetic disorder which impairs lung function, predisposes people to persistent airway infections and exposes them to acquiring multidrug resistant infections.

3 Aug 2026

Study reveals unexpected mechanism driving extreme antibiotic resistance

A patient with a severe infection is prescribed a potent antibiotic. Hopes for improvement are high, but just after treatment is given, resistance to the drug increases thousands of times. How could this happen?

23 Jul 2026

Patient-derived organoids uncover new targets for chronic pancreatitis treatment

Around three million people worldwide struggle with chronic pancreatitis, a condition wherein the pancreas becomes inflamed, scarred, and painful.

14 Jul 2026

Base editing technique reveals crucial gene for early human development

Research led by the University of Cambridge Loke Centre for Trophoblast Research has shown that a genome editing technique can be used to alter a single gene in human embryonic cells, enabling the study of very early human development in unparalleled detail.

25 Jun 2026

Prenatal therapy for cystic fibrosis improves lifelong health outcomes

This Cystic Fibrosis Awareness Month, Children's Hospital Colorado (Children's Colorado) is highlighting a growing shift in care: starting cystic fibrosis treatment before birth to improve lifelong health outcomes and reduce hospital stays.

27 May 2026

Early lung damage patterns uncovered in children with cystic fibrosis

Researchers have mapped how lung damage begins early in life for children with cystic fibrosis, providing new insights that will help reshape future care.

24 May 2026

Recent advancements in the development of models to study primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare non-communicable disorder that affects the liver. Chronic inflammation in and around the bile duct is followed by the development of fibrotic obstructions within the duct, causing bile to accumulate within the liver.

19 May 2026

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company's lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome.

From Enterprise Therapeutics Ltd 12 May 2026

Researchers pioneer breakthrough therapy for life-threatening infections

A revelatory treatment for patients with life-threatening infectious diseases is being pioneered in Melbourne by researchers at The Alfred and Monash University.

25 Apr 2026

Cystic fibrosis therapies significantly reduce the need for pediatric lung transplants

Pediatric lung transplant specialist Christian Benden, MD, described the future for children who need lung transplants: fewer operations overall, but more complex patients and mounting challenges for the teams who care for them. He addressed the 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) today in Toronto.

22 Apr 2026

New mechanism disables antibiotic resistance and cross-protection in bacteria

A newly discovered mechanism renders antibiotic-resistant bacteria vulnerable by disabling both their individual resistance and a process known as cross-protection, the ability of resistant bacteria to shield nearby, otherwise sensitive strains.

21 Apr 2026

Polygenic embryo testing raises ethical concerns beyond disease prevention

For more than four decades, in vitro fertilization (IVF) has helped families have children. Scientists estimate that more than 10 million people worldwide have been born through IVF and related assisted reproductive technologies, according to the International Committee for Monitoring Assisted Reproductive Technologies.

31 Mar 2026